【摘要】 目的探讨瑞波西汀与帕罗西汀治疗抑郁症的临床疗效和安全性。方法将60例抑郁症患者随机分为两组各30例,研究组口服瑞波西汀,对照组口服帕罗西汀,观察8周。于治疗前及治疗1、2、4、6、8周末用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末研究组总有效率86.67%,对照组83.33%。两组差异无显著性(P>0.05)。两组治疗各时段汉密顿抑郁量表总分均较治疗前有显著下降,差异有统计学意义(P<0.05,P<0.01)。治疗1周、2周研究组较对照组下降显著(P<0.05),其他时段无统计学意义(P>0.05)。两组不良反应均较轻微,多出现在治疗初期。研究组发生率为23.33%,对照组发生率为26.67%,差异无统计学意义(P>0.05)。结论瑞波西汀与帕罗西汀治疗抑郁症疗效显著,安全性高,依从性好,并且瑞波西汀起效较帕罗西汀迅速。更多还原

【Abstract】 Objective To explore the clinical efficacy and safety of reboxetine and paroxetine in the treatment of depression.Meth-ods Sixty cases were randomly divided into research group(n=30)that was given orally reboxetine and control group(n=30)that was given paroxetine for 8 weeks.The curative efficacy was assessed with the Hamilton Depression Scale(HAMD) and the adverse reactions with the Treatment Emergent Symptom Scale (TESS) before treatment and at the ends of 1, 2, 4 ,6 and 8 weeks.Results After 8 week treatment, the total effective rate of the research group was 86.67% and that of the control group was 83.33%, with no significant difference (P>0.05).The HAMD total scores of both groups were significantly lowered at every time points after treatment compared with pre-treatment, with a significant difference (P<0.05 or P<0.01).The scores of the research group were significantly lowered at Weeks 1and 2 than those of the control group(P<0.05), with no significant difference at other time points(P>0.05).Adverse reactions of both groups were mild.Conclusion Both reboxetine and paroxetine have evident effects, higher safety and better compliance in the treatment of depression, but the former shows a faster effect.更多还原